IPHARMA was authorized to conduct a Phase IIa clinical trial
IPHARMA was authorized by the Ministry of Healthcare of the Russian Federation to conduct a Phase IIa clinical trial of the drug Istaroxime (PST2744) (Windtree Therapeutics, Inc.).
Protocol № 04-CL-1904 "A multicenter randomized double-blind placebo-controlled parallel group study on the safety and efficacy of Istaroxime in patients with pre-cardiogenic shock (SEISMiC)".
The study will be conducted in healthcare facilities of Moscow.
